Prevalence of respiratory bacterial infections in people with lower respiratory tract infections in Africa: the BARIAFRICA systematic review and meta-analysis protocol

Tchatchouang, Serges; Bigna, Jean Joël; Nzouankeu, Ariane; Fonkoua, Marie‐Christine; Nansseu, Jobert Richie; Ndangang, Marie S.; Kenmoe, Sébastien; Penlap, Véronique; Njouom, Richard

doi:10.1136/bmjopen-2018-023592

Cited by 11 publications

(7 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Actualmente no se dispone de estudios poblacionales que permitan conocer la prevalencia de la enfermedad en España, aunque investigaciones realizadas en algunas zonas geográficas del país, tanto en niños como en adultos, parecen confirmar la variabilidad en la prevalencia observada en otros países 14 , 20 , 21 , 22 . Además, conocer la epidemiología de una enfermedad es un factor para establecer estrategias asistenciales, docentes e investigadoras 57 , 58 . Partiendo de esta evidencia, el objetivo principal de nuestro estudio es estimar la prevalencia de asma en población adulta de España realizando un estudio transversal bietápico.…”

Section: Discussionunclassified

Estudio de prevalencia de asma en población general en España

Blanco-Aparicio¹,

García-Río²,

González-Barcala³

et al. 2023

Open Respiratory Archives

View full text Add to dashboard Cite

Section: Discussionunclassified

Estudio de prevalencia de asma en población general en España

Blanco-Aparicio¹,

García-Río²,

González-Barcala³

et al. 2023

Open Respiratory Archives

View full text Add to dashboard Cite

“…Bacterial lower respiratory tract infection (LRTI) is one of the prevalent leading causes of mortality, especially in underdeveloped regions 1 and among children and the elderly. 2,3 Additionally, viruses that cause respiratory illnesses, such as SARS-CoV-2, can lead to severe bacterial coinfections in the lungs.…”

Section: ■ Introductionmentioning

confidence: 99%

Disposable Peptidoglycan-Specific Biosensor for Noninvasive Real-Time Detection of Broad-Spectrum Gram-Positive Bacteria in Exhaled Breath Condensates

Zhang,

Qi,

et al. 2024

Anal. Chem.

View full text Add to dashboard Cite

Rapidly identifying and quantifying Gram-positive bacteria are crucial to diagnosing and treating bacterial lower respiratory tract infections (LRTIs). This work presents a field-deployable biosensor for detecting Gram-positive bacteria from exhaled breath condensates (EBCs) based on peptidoglycan recognition using an aptamer. Dielectrophoretic force is employed to enrich the bacteria in 10 s without additional equipment or steps. Concurrently, the measurement of the sensor’s interfacial capacitance is coupled to quantify the bacteria during the enrichment process. By incorporation of a semiconductor condenser, the whole detection process, including EBC collection, takes about 3 min. This biosensor has a detection limit of 10 CFU/mL, a linear range of up to 105 CFU/mL and a selectivity of 1479:1. It is cost-effective and disposable due to its low cost. The sensor provides a nonstaining, culture-free and PCR-independent solution for noninvasive and real-time diagnosis of Gram-positive bacterial LRTIs.

show abstract

“…China, cross-sectional analysis, urinary tract infections during pregnancy, drug treatment models, real world 1 Background Urinary tract infections (UTIs) are common in expectant women, and even asymptomatic infections can cause severe complications for the mother and fetus, including low birth weight, premature birth, stillbirth, preeclampsia, maternal anemia, sepsis, and amnionitis (Bigna et al, 2018;Tchatchouang et al, 2019;Ali et al, 2022). Increased likelihood of developing a UTI during pregnancy is attributable to alterations in expectant women's physiology and lowered immunity (Delzell and LeFevre, 2000;Hill et al, 2005;Haider et al, 2010;Kalinderi et al, 2018;Storme et al, 2019;Getaneh et al, 2021).…”

Section: Introductionmentioning

confidence: 99%

Real world drug treatment models for pregnancy complicated with urinary tract infection in China from 2018 to 2022: a cross-section analysis

Jin,

Li,

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

Objective: Urinary tract infection (UTI) is common in pregnant women. The selection of anti-infection plans during pregnancy must take into account the dual factors of patient pregnancy status and urinary tract infection anti-infection treatment, as well as the efficacy, cost, risk, and potential adverse reactions associated with each method applied to individual patients. Consequently, there are numerous drugs from which to choose; presently, there is no unified conclusion regarding the choice of drug therapy, and there is a lack of long-term drug treatment for UTI during pregnancy. Our objective is to investigate the actual drug treatment patterns of UTI patients during pregnancy in China over the past 5 years, with a particular emphasis on the trend and rationality of antibiotic use in these patients over the past 5 years.Method: We conducted a cross-sectional analysis of data from a China Medical Association-supervised hospital prescription analysis cooperation initiative. From January 2018 to December 2022, the information is extracted from prescriptions/medical orders of patients with UTI during pregnancy. Using a primary anatomical therapeutic chemistry (ATC) classification code and the US Food and Drug Administration (FDA) classification, we quantified the frequency of drug use and drug types. We also calculated the prevalence of the most frequently prescribed antibacterial medications and assessed the efficacy of anti-infection plans based on drug labels and guidelines.Results: Among the 563 patients included in this research, Chengdu (36.59%), Guangzhou (27.72%), and Shanghai (8.70%) were the top three cities. Over the course of 5 years, the average age was 29.60% ± 6.59 years, with approximately 60.21% of women between the ages of 25 and 34. Each patient’s primary anti-infection medications were statistically analyzed. Cephalosporins (403, 71.58%), enzyme inhibitors (66, 11.72%), and penicillins (34, 6.04%) were the first few categories, followed by the most commonly used cephalosporins. Cefuroxime, ceftriaxone, and cefdinib, rounded out the top five. Cefoxitin and cefaclor. According to the 5-year change in dosage, cephalosporins have always ranked first. Three of the top five most expensive drugs are cephalosporins, carbapenems, and enzyme inhibitors. Teicoplanin, tigecycline, nifurtel, linezolid, and quinolones ranked among the top five in terms of per-patient drug costs for patients receiving comprehensive treatment drugs.Conclusion: In the 5 years of research, the average age of patients who visit a doctor has not increased substantially, but the opportunity cost of female fertility has increased, which has severely impeded the fulfillment of fertility desires. The selection of medications is generally reasonable, and the dosage of the first-line cephalosporins recommended by the guidelines is relatively high in this study. The dosage of furantoin and fosfomycin, which are more prevalent in urinary tract infections, is however relatively low. In addition, some expensive pharmaceuticals may increase patients’ financial burden. On the premise of meeting clinical needs, future research will focus on how to further improve the level of rational drug use in outpatient clinics, attain economical, safe, and effective drug use, and thus reduce the economic burden on patients.

show abstract

Prevalence of respiratory bacterial infections in people with lower respiratory tract infections in Africa: the BARIAFRICA systematic review and meta-analysis protocol

Cited by 11 publications

References 13 publications

Estudio de prevalencia de asma en población general en España

Estudio de prevalencia de asma en población general en España

Disposable Peptidoglycan-Specific Biosensor for Noninvasive Real-Time Detection of Broad-Spectrum Gram-Positive Bacteria in Exhaled Breath Condensates

Real world drug treatment models for pregnancy complicated with urinary tract infection in China from 2018 to 2022: a cross-section analysis

Contact Info

Product

Resources

About